Results of a prospective, multicenter study evaluating quality of life, safety, and efficacy of sacral neuromodulation at twelve months in subjects with symptoms of overactive bladder. Issue 2 (24th December 2014)

• Record Type: Journal Article
• Authors: Noblett, Karen; Siegel, Steven; Mangel, Jeffrey; Griebling, Tomas L.; Sutherland, Suzette E.; Bird, Erin T.; Comiter, Craig; Culkin, Daniel; Bennett, Jason; Zylstra, Samuel; Kan, Fangyu; Berg, Kellie Chase
• Is Part Of: Neurourology and urodynamics. Volume 35:Issue 2(2016:Feb.)
• Page Start: 246
• Page End: 251
• Publication Date: 2014-12-24
• Subjects: overactive bladder -- quality of life -- sacral neuromodulation -- urgency frequency -- urinary incontinence; Urinary organs -- Periodicals; Urodynamics -- Periodicals; Urology -- Periodicals; 616.6
• DOI: 10.1002/nau.22707
• Languages: English
• ISSNs: 0733-2467

Abstract

Abstract : Aims: This prospective, multicenter post‐approval study evaluated the success rate of sacral neuromodulation (SNM) with the InterStim® System at 12‐months. Subjects with bothersome symptoms of overactive bladder (OAB) including urinary urge incontinence (UI) or urgency‐frequency (UF), who failed at least one anticholinergic medication and had at least one not tried were included. Methods: Subjects with successful test stimulation received an SNM implant. Therapeutic success (≥50% improvement in average leaks/day or voids/day or a return to normal voiding frequency [<8 voids/day]) and quality of life through 12 months were evaluated for implanted subjects. Results: Of the 340 subjects that went through test stimulation, 272 were implanted with SNM. Of these, 91% were female, mean age was 57, UI subjects had 3.1 ± 2.7 leaks/day, UF subjects had 12.6 ± 4.5 voids/day. The analysis which includes all implanted subjects with diary data at baseline and 12 months showed an OAB therapeutic success rate of 85% at 12 months. UI subjects had a mean reduction of 2.2 ± 2.7 leaks/day; UF subjects had a mean reduction of 5.1 ± 4.1 voids/day (both P < 0.0001). Subjects showed significant improvement from baseline in all measures of ICIQ‐OABqol (all P < 0.0001). 80% of subjects reported improved changes in their urinary symptom interference at 12 months. Device‐related adverse events occurred in 16% (56/340) of subjects during test stimulation and 30% (82/272) of subjects post‐implant. Conclusions: This multicenter study shows SNM is safe and effective and results in improved outcomes through 12 months in subjects with OAB symptoms, without requiring failure of all medications. Neurourol. Urodynam. 35:246–251, 2016 . © 2014 The Authors. Neurourology and Urodynamics published by Wiley Periodicals, Inc.